TNFRSF8 and B-cell non-Hodgkin lymphoma: In SGN35-012, among patients with B-cell NHL treated with BV monotherapy, the ORR was 36% both in patients with CD30 expression ≥10% (17/47; 95% CI, 22.7%-51.5%) and in the CD30 <10% group (24/66; 95% CI, 24.9%-49.1%) (P = .983).